J Clin Pathol Qual Control.  2000 Jun;22(1):11-18.

Annual Report on External Quality Assessment of Clinical Microbiology Laboratory in Korea (1999)

• Kim EC
• Kang JO
• Kim M
• Kim MJ
• Kim SI
• Lee KW
• Lee DH
• Lee JH
• Lee NY
• Lee CK
• Shin CH
• Chang CH
• Choi HS

Abstract

Two trials of external quality assessment for clinical microbiology laboratory were performed in 1999. A total of ten specimens were distributed. Five specimens were distributed to 219 laboratories with 202 returns in Trial I and five specimens to 222 laboratories with 199 returns in Trial II. The percentages of fully correct identification of S. aureus, M. luteus, S. bovis, E. coli, P. aeruginosa, P. vulgaris, S. aureus, E. gallinarum, K. pneumoniae, S. marcescens, and P. aeruginosa were 98.0%, 18.8%, 48.5%, 98.5%, 95.5%, 97.0%, 35.7%, 98.0%, 97.5%, and 89.0%, respectively. The acceptable percentages on disk-diffusion antibacterial susceptibility tests against oxacillin and vancomycin of S. aureus (MB9901) in Trail I were 96.8% and 86.6%, respectively. Those against ampicillin and gentamicin of E. coli (MB9903) were 87.7% and 88.5%, respectively. Those against piperacillin and tobramycin of P. aeruginosa (MB9904) were 77.9% and 88.8%, respectively. those against cephalothin and amikacin of P. vulgaris (MB9905) were 34.4% and 100%, respectively. In Trial II, the performance on antimicrobial susceptibility showing more than 90% acceptable percentages was improved except that (63.5%) against vancomycin of E. gallinarum and that (58.6%) against imipenem of S. marcesscens.

MeSH Terms

Amikacin
Ampicillin
Cephalothin
Gentamicins
Imipenem
Korea*
Oxacillin
Piperacillin
Pneumonia
Tobramycin
Vancomycin
Amikacin
Ampicillin
Cephalothin
Gentamicins
Imipenem
Oxacillin
Piperacillin
Tobramycin
Vancomycin